CEREVEL THERAPEUTICS HOLDINGS, INC.
222 Jacobs Street, Suite 200
Cambridge MA 02141
VIA EDGAR
November 18, 2021
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: Cerevel Therapeutics Holdings, Inc.
Acceleration Request for Registration Statement on Form S-3
Filed November 10, 2021
File No. 333-260945
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cerevel Therapeutics Holdings, Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to November 22, 2021, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable.
If you have any questions regarding this request, please contact Arthur McGivern of Goodwin Procter LLP at (617) 570 1971.
| Sincerely, |
| CEREVEL THERAPEUTICS HOLDINGS, INC. |
| /s/ N. Anthony Coles |
| N. Anthony Coles |
| Chief Executive Officer |
cc: Scott M. Akamine, Cerevel Therapeutics Holdings, Inc.
John Mei, Cerevel Therapeutics Holdings, Inc.
Stuart M. Cable, Goodwin Procter LLP
Arthur R. McGivern, Goodwin Procter LLP